We hypothesized that the administration of the superoxide dismutase (SOD) mimetic Tempol (4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) may reverse diabetes-induced erectile dysfunction. To test this hypothesis, reactive oxygen species-related genes (SOD1, SOD2, GP Â 1, CAT, NOS2, NOS3) were tested, erectile functional studies and immunohistochemical analysis were carried out in diabetic rats treated with or without Tempol. Thirty Sprague-Dawley (3-4months old) rats were divided into three groups (n ¼ 10 each), 20 with diabetes (diabetic control and Tempol treatment) and 10 healthy controls. At 12 weeks after the induction of diabetes by streptozotocin and Tempol treatment, all groups underwent in vivo cavernous nerve stimulation. Rat crura were harvested and the expression of antioxidative defense enzymes were examined by semi-quantitative reverse transcriptase PCR (RT-PCR). To confirm the RT-PCR results, we carried out immunohistochemistry (IHC) for catalase (CAT) and iNOS (NOS2). Nitration of tyrosine groups in proteins was also examined by IHC. Mean intracavernous pressure in the diabetic group was significantly lower than in the healthy controls (P o0.001) and was reversed by Tempol treatment (P o0.0108). NOS2 protein expression was significantly increased in diabetic animals compared with healthy controls and Tempol restored NOS2 protein level. Nitrotyrosine was also higher in diabetic animals and although Tempol treatment decreased its formation, it remained higher than that found in healthy controls. This study suggests that Tempol treatment increased erectile function through modulating oxidative stress-related genes in diabetic rats. This is the first report about the relationship between diabetes-induced erectile dysfunction and oxidative stress, and antioxidative therapy using the superoxide dismutase mimetic, Tempol, to restore erectile function.
Introduction
There are 23.6 million children and adults in the United States, or 7.8% of the population, who have diabetes. Although an estimated 17.9 million have been diagnosed with diabetes, 5.7 million people (or nearly one quarter) are unaware that they have the disease.
1 It has been estimated that 50-75% of males with diabetes have erectile dysfunction (ED). 2 In men, ED is one of the major complications of diabetes.
The penis is a richly vascularized organ, and penile erection is, in large part, a vascular event. Recent reports show that in men with diabetes mellitus, ED is an early event and a potential marker for cardiovascular disease. 3 Data from several studies involving diabetic patients with cardiac disease have shown a high prevalence (42-75%) of ED in the patient population. In addition, a recent report showed incidence rates of occult cardiovascular disease in men with ED as high as 15-30%. 4 Therefore, ED is considered to be an early manifestation of systemic endothelial dysfunction.
The cause of diabetes-induced ED is multifactorial and its mechanisms are not fully understood. The first-line treatment, phosphodiesterase type 5 inhibitor (for example, sildenafil, vardenafil and tadalafil), is widely used as a medicine to maintain an erection, but in diabetes its effect is clearly reduced when compared with non-diabetic men. 5 Oxidative stress occurs when reactive oxygen and nitrogen species (ROS and RNS, respectively) production is excessive and/or defense mechanisms fail. ROS are kept under control by an endogenous system of protection that consists of scavenger enzymes (superoxide dismutase, catalase, glutathione peroxidase) and antioxidants (vitamin E, b-carotene, ascorbic acid, glutathione).
A number of sources of ROS, in particular superoxide anion, have been identified in diabetes including non-enzymatic, for example, mitochondrial respiratory chain, glucose autoxidation, activation of polyol pathways, glycation formation of advanced glycation end products and enzymatic, for example, NAD(P)H oxidase, uncoupled eNOS, xanthine oxidase, cyclooxygenase. 6 It has been shown that oxidative damage due to hyperglycemia contributes to both macro and microvascular pathology in diabetes such as atherosclerosis, cardiovascular diseases, retinopathy, nephropathy and peripheral neuropathy. 7 A recent publication has suggested that there is a close relationship between oxidative stress and diabetic ED in both animal models and humans. 8 Natural antioxidants, in particular vitamin E, have shown little beneficial effect in clinical trials. 9 It has recently been suggested that antioxidant therapy with vitamin E or others is limited to scavenging already formed oxidants, particularly lipid peroxidation products. 10 Tempol (4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) is a low molecular weight, watersoluble, membrane permeable and metal-independent superoxide dismutase (SOD) mimetic, which has been widely used in electron spin resonance spectroscopy.
11
Tempol can penetrate cell membranes and react with both intra-and extracellular oxygen free radicals, resulting in protecting endothelial function. 12 This property makes Tempol attractive for treatment of diseases related to oxidative stress. Recent studies have indicated that Tempol can be used as an antioxidant in animal models to prevent many diseases that are caused by ROS such as ischemicreperfusion injury, inflammation and shock. 13 However in most of these experiments, Tempol has been administered before or at the time of onset of disease. Diabetes mellitus, a continuous hyperglycemia, is a chronic disease, therefore its complications are already established at the time of diagnosis. Our aim in this study was to assess whether delayed and chronic administration of an antioxidant superoxide scavenger such as Tempol would be effective as an intervention to diabetic ED complications. To our knowledge, there have been no reports about Tempol, ROS and its effect on ED. Figure 1 ). The development of diabetes was confirmed by blood glucose levels at 1 week after STZ injection. STZ-treated rats with a blood glucose level of below 250 mg per 100 ml were excluded from this study. Body weight and blood glucose levels in serum samples obtained from the tail vein were measured weekly. Tempol treatment was started at 6 weeks after the establishment of diabetes. Subcutaneous injections of 100 mg kg -1
Material and methods

Experimental animals
Tempol (Sigma-Aldrich, Inc.) were administered twice a day for 6 weeks.
This project was approved by the animal ethics committee (project number A3476-01).
Functional study
Erectile function was assessed by measurement of intracavernous pressure (ICP) after electro stimulation of the cavernous nerve. 14, 15 Briefly, after anesthesia by inhalation of sevoflurane (Baxter Healthcare Corporation, Deerfield, IL, USA), rats were placed in a supine position, and through a low abdominal midline incision, the lateral prostatic Oxidative stress in diabetes-induced erectile dysfunction T Kawakami et al space was exposed on each side. The major pelvic ganglia, pelvic nerves and cavernous nerves were identified and exposed. The skin overlying the penis was incised and the penile crura were exposed by removing part of ischiocavernous muscle and fascia. A 23-gauge needle filled with 250 U ml -1 heparin solution was inserted into the crura and connected to a pressure monitor with polyethylene tubing. The increase in ICP was measured and recorded using LabVIEW 5.0 (National Instruments, Austin, TX, USA) software. Electro stimulation was performed with a delicate stainless steel bipolar hook electrode and monophasic rectangular voltage pulses were delivered using a computer program. The stimulus parameters were 1.5 mA, 20 Hz frequency, pulse width 0.2 ms and a duration of 60 s. The cavernous nerve was stimulated 5 times at 4-min interval on each side. ICP was measured and recorded with Lab View 5.01 software (National Instruments). The ICP is defined as the maximal pressure obtained by stimulation minus the basal pressure before stimulation. The latency period is defined as the time between cavernous nerve stimulation and the onset of pressure rise inside the penile crura.
After the functional study was completed, a crura was obtained and incubated in RNAlater RNA Stabilization Reagent (QIAGEN Inc., Valencia, CA, USA) overnight at 4 1C, and on the next day, the samples were frozen in liquid nitrogen and stored at À80 1C until processed for mRNA expression analysis. The crura of the other side was placed in a 4% formaldehyde solution for immunohistochemical studies of cavernous tissue. After the procedure, the rats were killed by thoracotomy.
RNA isolation
Total RNA was isolated using a combination of TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) and RNeasy Mini Kit (QIAGEN Inc.,) previously as described. 16 Tissue was homogenized in TRIzol reagent, chloroform was added and centrifugation was performed to improve recovery of the aqueous phase of the solution. Ethanol (100%) was added to an equal volume of the recovered aqueous solution and the mixture was added to an RNeasy minicolumn. All subsequent steps were performed as described by the supplier (QIAGEN RNeasy Mini hand book, third edition). The concentration and quality of RNA was measured by spectrophotometric analysis at 260 and 280 nm.
RT-PCR
Total RNA was reverse transcribed into cDNA with the use of Reverse Transcription System (Promega Corporation, Madison, WI, USA) using oligo(dT) as primers. Antioxidative enzyme, such as Cu/ZnSOD (SOD1), MnSOD (SOD2), glutathione peroxidase (GP Â 1) and catalase (CAT), and also nitric oxide synthase, inducible (iNOS; NOS2) and endothelial (eNOS; NOS3) were analyzed by a semi-quantitative method.
Primer sets used for reverse transcriptase PCR (RT-PCR) are shown in Table 1 . PCR cycle 
Immunohistochemistry
Immunostaining was performed on formalin-fixed, paraffin-embedded rat crura tissue sections. Sections of 5 mm thickness were deparaffinized with xylene and rehydrated in graded alcohols followed by rinsing with distilled water. Antigen retrieval was carried out by autoclaving the slides in 10 mM sodium citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked with 3% H 2 O 2 . Incubation with goat anti-rabbit serum (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used to block non-specific protein binding. The nitrotyrosine antibody (rabbit polyclonal IgG, cat# 06-284, Upstate Cell Signaling solutions, Lake Placid, NY, USA) was diluted to 2.5 mg ml -1 and incubated with slides overnight. To confirm the RT-PCR results, we carried out immunohistochemistry (IHC) for CAT (#ab52477, Abcam, Cambridge, MA, USA) and iNOS (NOS2) (#53584, Anaspec, San Jose, CA, USA). Omitting the primary antibody was used as negative control. Slides were then incubated with biotinylated secondary antibody to IgG (Santa Cruz Biotechnology). After washing, the slides were next incubated with horseradish peroxidase-streptavidin (Santa Cruz), washed and stained with diaminobenzidine (LAB Vision Corporation, Fremont, CA, USA) and counterstained with hematoxylin.
Statistics
All data are expressed as the mean ± s.e. and were analyzed using analysis of variance with Bonferroni/Dunn post hoc test for multiple group comparisons on Statview 5. 0. 1(SAS Institute, Cary, NC, USA).
Results
Development of diabetes
At 12 weeks after STZ injections, diabetic rats (diabetic control and Tempol treatment) were significantly lighter in body weight than age-matched healthy controls (452.0±6.6, 448.6±21.8 vs 603.6±11.8 gm, P o0.05) and had higher levels of blood glucose (361.8 ± 18.2, 368.7 ± 19.7 vs 109.4±4.0 mg per 100 ml, P o0.05). They also showed the usual signs of diabetes such as polydipsia and polyuria. In diabetic rats, Tempol injections did not have a significant effect on body weight or on blood glucose levels. Figure 1 shows erectile function in diabetic, healthy control and Tempol-treated rats. Maximum ICP in diabetes was generally lower compared with that observed in healthy controls (78.8±5.6 vs 130.5 ± 4.8 cm H 2 O, P o0.05). In addition, the pressure was not maintained and declined even further with time. Tempol treatment partially restored ICP in diabetic ED (101.7 ± 5.6 vs 78.8 ± 5.6 cm H 2 O, P o0.05). Tempol treatment reversed about 44.3% of the diabetes-induced reduction in ICP. Figure 2 shows the relative levels of SOD1, SOD2, GP Â 1, CAT, NOS2 and NOS3 mRNA transcripts in the penile rat crura. SOD2 mRNA expression was significantly lower in diabetic rats compared with healthy controls (Figure 3b ). Tempol-treated diabetic rats had increased mean levels of SOD2 mRNA expression. CAT mRNA expression in diabetic rats was significantly lower compared with healthy controls (Figure 3d ). Tempol-treated animals had CAT mRNA levels similar to those in healthy controls. NOS2 (iNOS) mRNA expression in diabetic rats was significantly higher compared with healthy controls (Figure 3e ). Tempol-treated rats had NOS2 mRNA levels lower than that of healthy controls.
Erectile function
RT-PCR analysis
SOD1, GP Â 1 and NOS3 mRNA expression did not significantly change among diabetic animals, healthy controls and the Tempol-treated group (Figures 3a, c and f) .
Immunohistochemistry of rat crura
To confirm the RT-PCR results, we carried out IHC for CAT and NOS2 (iNOS). We did not find a Oxidative stress in diabetes-induced erectile dysfunction T Kawakami et al significant difference in CAT expression between diabetes mellitus and the Tempol treatment groups (data not shown). However, NOS2 protein levels were dramatically decreased in the Tempol-treated group and this result was similar to the RT-PCR results. Typical NOS2 (iNOS) immunostaining is shown in Figure 4 . NOS2 (iNOS) was stained in penile cavernosal smooth muscle and endothelium. Figure 5 shows that nitrotyrosine protein expression in the artery wall and smooth muscle cells was higher in diabetic rats than in healthy controls. Tempol treatment decreased nitrotyrosine formation but not to healthy control levels.
Discussion
This is the first report to show the relationship between diabetes-induced ED, oxidative stress and antioxidative therapy using the superoxide dismu- Tempol Figure 3 Mean quantitative gene expression of SOD1 (a), SOD2 (b), GP Â 1 (c), CAT (d), NOS2 (e) and NOS3 (f) was analyzed using densitometry. In SOD1 mRNA expression there was no significant change among healthy controls, diabetes mellitus (DM) controls and the Tempol (4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) treatment group. However, SOD2 mRNA expression in DM was significantly lower than that of healthy controls, and Tempol treatment partially restored its expression but did not reach significance. Glutathione peroxidase (GP Â 1) mRNA expression (c) was similar in all groups. CAT mRNA expression (d) in DM was significantly lower than that of healthy controls and Tempol treatment restored CAT to healthy control level. NOS2 mRNA expression (e) in DM was significantly higher than that of healthy controls and Tempol treatment mRNA was lower than healthy controls. In NOS3 mRNA expression (f), there was no significant change among diabetes, healthy control and Tempol treatment group. Note: (a, b)*healthy control vs DM, P ¼ 0.003; (c, d)*healthy control vs DM, P ¼ 0.03; **DM vs Tempol treatment, P ¼ 0.01; (e, f)*healthy control vs DM, P ¼ 0.01; **DM vs Tempol treatment, Po0.0001.
Oxidative stress in diabetes-induced erectile dysfunction T Kawakami et al tase mimetic, Tempol, to restore erectile function. Diabetic ED involves several factors, including NO, ROS, NOS (NOS1, NOS2 and NOS3), peroxynitrite and others. Nitric oxide (NO), a vasodilator, is a principal mediator in the initiation and maintenance of penile erection. NO production plays a central role in modulating endothelial function. 17 Decreased relaxation of the cavernosal tissue in experimental diabetic animals is associated with a lack of NO bioavailability. 18 Vascular endothelial cells are an important target of hyperglycemic damage. It has been shown that hyperglycemia increases the production of ROS inside cultured bovine aortic endothelial cells. 19 A recent study showed that the hyperglycemia-induced process of overproduction of superoxide at the mitochondrial level is the initial and key event in the activation of all other pathways involved in the pathogenesis of diabetic complications. 20 Hyperglycemia also favors increased expression of iNOS (NOS2) through the activation of stresssensitive pathways such as NF-êB, which can increase the generation of NO. 21 Superoxide immediately interacts with NO, generating cytotoxic peroxynitrite (ONOOÀ), thereby reducing the efficacy of the potent endothelium-derived vasodilator system that participates in the homeostatic regulation of the vasculature. Peroxynitrite, a potent oxidative stress inducer, leads to the iNOS (NOS2) and eNOS (NOS3) uncoupled state due to a deficiency of tetrahydrobiopterin (BH4), a NOS cofactor, resulting in the production of superoxide rather than NO. 7 It has also been shown that peroxynitrite induces nitrotyrosine formation, lipid
Control
Tempol DM Figure 4 Representative immunohistochemical staining of rat corpus cavernosum of NOS2 (iNOS). Smooth muscle and endothelium are stained brown in diabetic rats. Magnification is Â 100. DM, diabetes mellitus; Tempol, 4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl.
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Smooth muscle Figure 5 Immunohistochemistry of anti-nitrotyrosine. Nitrotyrosine protein expression in the artery wall and smooth muscle cells of rat crura was higher in diabetic rats than in healthy controls. Tempol (4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) treatment decreased nitrotyrosine formation. Magnification is Â 200. DM, diabetes mellitus.
Oxidative stress in diabetes-induced erectile dysfunction T Kawakami et al peroxidation, DNA strand breakage and consequent activation of the nuclear enzyme poly (ADP-ribose) polymerase (PARP). PARP activation in turn depletes the intracellular concentration of its substrate NAD þ , slowing the rate of glycolysis, electron transport and ATP formation, and produces the ADP rybosylation of GADPH, resulting in endothelial dysfunction. 22 On the basis of this evidence, we examined the mRNA and protein levels of antioxidative enzymes in control, diabetes and Tempol-treated rats to confirm the effect of Tempol on rat crura.
We observed decreased CAT mRNA expression in diabetes but there was no change in CAT protein levels between control and diabetes. We did not examine CAT activity, however, our results may suggest that Tempol does not affect CAT expression.
In our study, NOS2 (iNOS) mRNA and protein levels increased in diabetic rats and this result is consistent with a previous report. 23 In addition, the protein expression level of iNOS (NOS2) was restored in Tempol-treated rats. We also found higher nitrotyrosine protein expression in diabetic rats in the artery wall and smooth muscle cells with decreased nitrotyrosine protein levels in Tempoltreated rats. However, it is unknown why Tempol affected peroxynitrite expression levels. Additonal studies are needed to address this.
Under potent oxidative stress conditions such as diabetes, peroxynitrite induces NOS2 (iNOS) and nitrotyrosine in various tissues. [24] [25] [26] Nitrotyrosine formation mediates apoptosis and pathological angiogenesis in endothelial cells. [27] [28] [29] A previous report from our laboratory suggested that diabetic rats have enhanced apoptotic activity in rat crura. 30 In this study, we did not perform apoptosis analysis in Tempol-treated rats crura. However, our results showing that hyperglycemia induced nitrotyrosine formation and NOS2 production suggest that there may be increased apoptosis in diabetic rat crura. Thus, Tempol might inhibit apoptosis in diabetic rat crura and restore endothelial function.
In this study, Tempol treatment was started at 6 weeks after the onset of diabetes. Our previous results have indicated that low ICP was observed 4 weeks after the onset of diabetes. 30 As diabetes is a chronic disease, Tempol was administered to rats with established diabetes-induced ED. The delayed and continuous Tempol treatment regimen used in this study partially restored erectile function but we hypothesize that if Tempol was administered before or at the onset of diabetes, its effect might be more dramatic.
In conclusion, the administration of Tempol to diabetic rats inhibited superoxide overproduction. It also reversed the increase of iNOS mRNA expression in rat crura and release of nitric oxide from endothelial cells leading to decreased formation of peroxynitrite. In addition, decreased peroxynitrite lead to functional restoration of endothelial cells and in turn erectile function. Suppression of oxidative stress is potentially a new strategy for treating diabetes-induced ED.
